Article

Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC Organoids

2023-04-03

Abstract excerpt

Aberrant alternative splicing is emerging as a cancer hallmark and a potential therapeutic target. It is the result of dysregulated splicing factors or genetic alterations in splicing-regulatory cis -elements. Targeting individual altered splicing events associated with cancer-cell dependencies is a potential therapeutic strategy, but several technical limitations need to be addressed. Patient-derived organoids (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f4b42a23-081c-5446-aa6f-6ba8fa0332a5
DOI: 10.1101/2023.03.31.535161

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC OrganoidsDOI 10.1101/2023.03.31.535161Read

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic FrontiersSemantic proximity Read

Delivery is key: lessons learnt from developing splice‐switching antisense therapiesSemantic proximity Read

Targeting CPSF73, the mRNA 3’ End Processing Endonuclease, Moves Cancer Cells Away from the Mesenchymal StateSemantic proximity Read

Personalized RNA Medicine for Pancreatic CancerSemantic proximity Read

Rapid and scalable preclinical evaluation of personalized antisense oligonucleotide therapeutics using organoids derived from rare disease patientsSemantic proximity Read

The Versatile Applications of Antisense Oligonucleotides in Modern MedicineSemantic proximity Read

Therapeutic Potential of Splice-Switching OligonucleotidesSemantic proximity Read

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read

Rapid and scalable personalized ASO screening in patient-derived organoids.Semantic proximity Read

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drugSemantic proximity Read

Overview on applications of antisense-mediated exon skipping.Semantic proximity Read

Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Semantic proximity Read